Aclidinium bromide plus formoterol for the treatment of chronic obstructive pulmonary disease

Abstract

Introduction: Drugs that target dynamic hyperinflation such as long-acting β-2 agonists and long-acting antimuscarinic antagonists form a cornerstone of chronic obstructive pulmonary disease (COPD) management. The idea of combining these two medications in a single formulation, which may potentially improve patient compliance, is novel and attractive.

Areas covered: The pharmacologic profiles of aclidinium bromide and formoterol fumarate are discussed. However, studies to define drug interactions and alterations in the pharmacodynamics and pharmacokinetics of the fixed dose combination (FDC) of aclidinium bromide/formoterol fumarate in large populations remain unpublished. Results of Phase II and two Phase III pivotal trials, ACLIFORM/COPD and AUGMENT COPD, evaluating the FDC are discussed.

Expert opinion: Initial data for the aclidinium/formoterol inhaler appears to be promising for impacting the lung function. To define if this benefit translates into improved long-term outcomes of decreased exacerbation frequency, improved quality of life and decreased disease-specific mortality are important. The introduction of this combination will likely have a significant impact on the prescribing habits of physicians across the world.

Keywords:

• aclidinium bromide
• bronchodilators
• chronic obstructive pulmonary disease
• formoterol fumarate
• long-acting antimuscarinic antagonists
• long-acting β-2 agonists

View correction statement:

Erratum

Declaration of interest

C Strange is a consultant and received travel monies monies from Astra Zeneca, Baxter, CSL Behring and Grifols in the past year on subjects related to COPD. He has received grants from Acelion, Alpha-1 Association, Alpha-1 Foundation, CSL Behring, Entera Health, NIH and Pearl Therapeutics. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.